An interview on Czech Radio at 6:20 a.m. with neurologist Prof. MUDr. David Školoudík, Ph.D., FESO, FEAN, and David Maršálek, CEO and founder of H2 Global Group, discussing molecular hydrogen and the first clinical study of its kind in the Czech Republic.
H2 Medical Technologies is issuing a public call for volunteers who wish to participate in the study and meet the basic eligibility criteria:
-
age 50–80 years,
-
overall good health,
-
a diagnosis of mild cognitive impairment (MCI), or mild to moderate dementia,
-
preferably residence in Ostrava or the surrounding area, where the study will take place.
Participation in this study does not guarantee any health benefit and should not be considered a substitute for standard medical treatment. Interested individuals may apply until January 19, 2026, by emailing: david.skoloudik@H2medical.com
You can find the interview and the full article here: